Please assess the completion status of the following clinical trial:

Trial Title: Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 10 years and ≤ 50 years~* G6PD-normal defined by Carestart rapid diagnostic test or the OSMMR2000 G6PD qualitative test~* Absence of symptomatic falciparum malaria, defined by fever on enrolment~* Presence of P. falciparum gametocytes on thick blood film at a density \>16 gametocytes/μL (i.e. ≥ gametocytes recorded in the thick film against 500 white blood cells)~* Absence of other non-P. falciparum species on blood film~* Hemoglobin ≥ 10 g/dL~* Individuals weighing \< = 80 kg~* No evidence of acute severe or chronic disease~* Written, informed consent~Exclusion Criteria:~* Women who are pregnant or lactating (tested at baseline). Urine and/or serum pregnancy testing (β-hCG) will be used.~* Detection of a non-P. falciparum species by microscopy~* Previous reaction to study drugs / known allergy to study drugs~* Signs of severe malaria, including hyperparasitemia (defined as asexual parasitemia \> 100,000 parasites / μL)~* Signs of acute or chronic illness, including hepatitis~* The use of other medication (except for paracetamol and/or aspirin)~* Use of antimalarial drugs over the past 7 days (as reported by the participant)~* Clinically significant illness (intercurrent illness e.g., pneumonia, pre-existing condition e.g., renal disease, malignancy or conditions that may affect absorption of study medication e.g., severe diarrhea or any signs of malnutrition as defined clinically)~* Signs of hepatic injury (such as nausea and/or abdominal pain associated with jaundice) or known severe liver disease (i.e., decompensated cirrhosis, Child Pugh stage B or C)~* Signs, symptoms or known renal impairment~* Clinically significant abnormal laboratory values as determined by history, physical examination or routine blood chemistries and hematology values (laboratory guideline values for exclusion are hemoglobin \< 10 g/dL, platelets \< 50,000/μl, White Blood Cell count (WBC) \< 2000/μl, serum creatinine \>2.0mg/dL, or ALT or AST more than 3 times the upper limit of normal for age.~* Blood transfusion in the last 90 days.~* Consistent with the long half-life of tafenoquine, effective contraception should be continued for 5 half-lives (3 months) after the end of treatment.~* History of psychiatric disorders

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Artemether-lumefantrine (AL) (Type: ACTIVE_COMPARATOR): Subjects will receive artemether-lumefantrine (AL) twice daily for 3 days.
- AL with 0.25mg/kg primaquine (PQ) (Type: EXPERIMENTAL): Subjects will receive artemether-lumefantrine (AL) twice daily for 3 days and a single dose of 0.25mg/kg primaquine (PQ) on the first day of AL treatment.
- Sulphadoxine-pyrimethamine with amodiaquine (SPAQ) (Type: ACTIVE_COMPARATOR): Subjects will receive sulphadoxine-pyrimethamine with amodiaquine (SPAQ) once daily for 3 days.
- SPAQ with 1.66mg/kg tafenoquine (TQ) (Type: EXPERIMENTAL): Subjects will receive sulphadoxine-pyrimethamine with amodiaquine (SPAQ) once daily for 3 days and a single dose of 1.66mg/kg tafenoquine (TQ) on the first day of SPAQ treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).